Featured StoriesNewsPress Releases
Premier Biomedical Pain Relief Meds Products Now Available on Amazon in Addition to Their Website
El Paso, Texas, November 2, 2017 — Premier Biomedical, Inc. (OTCQB: “BIEI“) announced that their pain relief products, currently sold globally through their website, www.painreliefmeds.com, are now available on Amazon for shipment to North American destinations by searching Premier Biomedical. The company indicated that while their products will still be available for purchase through their website, the reach of Amazon as one of the largest market places in the world is expected to significantly boost their sales.
William A. Hartman, President and CEO of Premier Biomedical stated, “This is a significant step forward in our plans to make our world class products available to a wider audience, and allow us to advertise our products to interested parties. Since we launched our first pain relief product, our 96-hour skin patch, early this year, we have added three more topical pain relief products, two roll-on applicators – one oil based and one water based, and most recently an oil based spray to our product offering. We continue to explore and develop new pain relief products to meet customer needs and to provide viable alternatives to dangerous opioid pain killers.
“We still are exploring direct distribution channels throughout the United States and the world, to provide access to our products to those who are either unable or unwilling to purchase products through the internet, or to wait for delivery of their pain relief products,” Hartman concluded.
For more information please contact:
Amazon, Inc (NAS: AMZN) is a $150 billion online retailer that offers a wide range of products. The Company products include books, music, videotapes, computers, electronics, home and garden, and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers in North America and internationally, through retail Websites, such as amazon.com, amazon.ca, and amazon.com.mx among others.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products to address the rising opioid addiction problem, which they began selling in early 2017. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.